Endocrine Abstracts

Immune checkpoint inhibitors are a new group of monoclonal antibodies against checkpoints in normal T Lymphocyte activation enabling immune system activation in order to target cancer cells. First used for treatment of melanoma in 2011, they are currently indicated for management of an increasing spectrum of malignancy. Endocrinopathy secondary to checkpoint inhibitors is commonly observed. This has led to a new group of patients requiring specialist investigation, management, follow-up and advice/support. In addition, these patients may have pre-existing endocrine problems, receive glucocorticoid treatment for other immune related inflammatory adverse effects and need steroid safety advice, or may have an incidentally detected abnormality detected in an endocrine organ during their extensive long-term follow-up. The endocrine specialist nurse is integral to all these aspects and collaboration with oncology is essential for optimal patient outcomes.